26.79
0.02 (0.07%)
| Penutupan Terdahulu | 26.77 |
| Buka | 26.78 |
| Jumlah Dagangan | 1,543,306 |
| Purata Dagangan (3B) | 3,168,638 |
| Modal Pasaran | 1,426,323,456 |
| Harga / Pendapatan (P/E Ke hadapan) | 25.45 |
| Harga / Jualan (P/S) | 974.52 |
| Harga / Buku (P/B) | 49.03 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Aug 2026 |
| EPS Cair (TTM) | -3.69 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.98% |
| Nisbah Semasa (MRQ) | 10.44 |
| Aliran Tunai Operasi (OCF TTM) | -127.65 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -72.82 M |
| Pulangan Atas Aset (ROA TTM) | -58.15% |
| Pulangan Atas Ekuiti (ROE TTM) | -150.50% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | KalVista Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.00 |
|
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.47% |
| % Dimiliki oleh Institusi | 112.39% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |